Payment overview · 2025
General Payments
$6,889.13
52 reported records · 11 companies
Healthcare provider profile · identity verified
Keith K Woo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HONOLULU, HI · NPI 1366595092
Verified facts
What the public records show
CMS Open Payments records show Keith K Woo, M.D. received $6,889.13 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 64.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Kerendia, Linzess, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vemlidy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $4,431.06 | 64.3% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $713.43 | 10.4% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $517.85 | 7.5% | 8 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $444.21 | 6.5% | 13 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $149.98 | 2.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $141.24 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.00 | 1.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.85 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $95.35 | 1.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.16 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,125.00 | 3 |
| Food and Beverage | $2,764.13 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $3,275.09 | 14 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $1,386.43 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $411.21 | 7 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $305.53 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $286.05 | 3 | 2025 |
Source payment records
|
|||||
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $149.98 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $141.24 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $141.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Livdelzi Normalized: livdelzi |
Drug | Gilead Sciences, Inc. | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $121.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $95.35 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 197 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 53 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 165 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
197 | 56 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
165 | 59 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
248 | 57 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 857 | 231 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 845 | 255 |
| Amlodipine Besylate | Amlodipine Besylate | 723 | 185 |
| Metformin Hcl Er | Metformin Hcl | 545 | 148 |
| Vascepa | Icosapent Ethyl | 502 | 135 |
| Losartan Potassium | Losartan Potassium | 478 | 133 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 472 | 131 |
| Alendronate Sodium | Alendronate Sodium | 307 | 86 |
| Omeprazole | Omeprazole | 288 | 87 |
| Donepezil Hcl | Donepezil Hcl | 267 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 71 |
| Farxiga | Dapagliflozin Propanediol | 248 | 57 |
| Tramadol Hcl | Tramadol Hcl | 228 | 69 |
| Creon | Lipase/Protease/Amylase | 197 | 56 |
| Glimepiride | Glimepiride | 197 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 62 |
| Finasteride | Finasteride | 166 | 55 |
| Linzess | Linaclotide | 165 | 59 |
| Pregabalin | Pregabalin | 140 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 138 | 104 |
| Metformin Hcl | Metformin Hcl | 124 | 33 |
| Clobetasol Propionate | Clobetasol Propionate | 122 | 70 |
| Jardiance | Empagliflozin | 110 | 31 |
| Meclizine Hcl | Meclizine Hcl | 103 | 36 |
| Furosemide | Furosemide | 102 | 38 |
| Trazodone Hcl | Trazodone Hcl | 99 | 32 |
| Mirtazapine | Mirtazapine | 92 | 32 |
| Azithromycin | Azithromycin | 88 | 77 |
| Celecoxib | Celecoxib | 88 | 39 |
| Levofloxacin | Levofloxacin | 87 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 36 |
| Naproxen | Naproxen | 75 | 34 |
| Ezetimibe | Ezetimibe | 74 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 32 |
| Eliquis | Apixaban | 67 | 18 |
| Mupirocin | Mupirocin | 65 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 21 |
| Clonidine Hcl | Clonidine Hcl | 64 | 17 |
| Risedronate Sodium | Risedronate Sodium | 64 | 13 |
| Allopurinol | Allopurinol | 63 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 63 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 62 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 22 |
| Hydrocortisone | Hydrocortisone | 58 | 20 |
| Memantine Hcl | Memantine Hcl | 58 | 15 |
| Ketoconazole | Ketoconazole | 55 | 22 |
| Simvastatin | Simvastatin | 54 | 11 |
| Famotidine | Famotidine | 53 | 21 |
| Kerendia | Finerenone | 53 | 14 |
| Meloxicam | Meloxicam | 52 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | 13 |
| Januvia | Sitagliptin Phosphate | 51 | 11 |
| Lisinopril | Lisinopril | 51 | 19 |
| Gabapentin | Gabapentin | 45 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 30 |
| Montelukast Sodium | Montelukast Sodium | 43 | suppressed |
| Carvedilol | Carvedilol | 40 | 11 |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Livalo | Pitavastatin Calcium | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 36 | 19 |
| Loperamide | Loperamide Hcl | 36 | 18 |
| Atenolol | Atenolol | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 12 |
| Diclofenac Epolamine | Diclofenac Epolamine | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Baclofen | Baclofen | 26 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 17 |
| Latanoprost | Latanoprost | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 14 |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,889.13 · 52 records | ABBVIE INC. | CAPVAXIVE, CREON, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, JARDIANCE, KRYSTEXXA, Kerendia, LINZESS, Livdelzi, NEXLETOL, OMNIPOD, OTEZLA, REPATHA, REXULTI, TEZSPIRE, Yeztugo | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error